Adam Rosenbaum
Research Subjects
Research Interests
Adam Rosenbaum has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Aanal Bhatt
Ginkgo Bioworks, Inc, MA, USA
2 shared publications - Alexander Smith
Ginkgo Bioworks Inc
2 shared publications - Ammar Arsiwala
Ginkgo Bioworks, Inc, MA, USA
2 shared publications - Lucia Grippo
Ginkgo Bioworks, Inc, MA, USA
2 shared publications Olga Allen
Ginkgo Bioworks Inc
2 shared publications- Peter M. Tessier
Department of Chemical Engineering, University of Michigan
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 22 February 2026
- Published by Taylor & Francis in mAbs
- Vol. 18 (1) , 2634216
2025 Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization
Monoclonal antibodies (mAbs) are among the most successful therapeutic modalities, with over 200 marketed products and nearly 1400 candidates in clinical development.1 While high-affinity binding r...
- 22 February 2026
- Published by Taylor & Francis in mAbs
- Vol. 18 (1) , 2634216
Top Cited PapersOpen Access2025 Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization
Monoclonal antibodies (mAbs) are among the most successful therapeutic modalities, with over 200 marketed products and nearly 1400 candidates in clinical development.1 While high-affinity binding r...
- Open Access
- 2 December 2025
- Published by Taylor & Francis in mAbs
- Vol. 17 (1) , 2593055
A high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training
Antibodies must bind their targets with high affinity and specificity to achieve useful therapeutic activity. They must also possess suitable developability properties (e.g. thermostability, solubility, viscosity, polyreactivity) to ensure favorable manufacturing, formulation, and in vivo performance. Both binding and developability properties are inherent to a given antibody amino acid sequence. Identification or selection of antibodies possessing suitable-binding characteristics is now routine, and de novo computational design models, trained on extensive complementarity-determining region sequence and structural data, are rapidly improving. Developability properties, however, remain difficult to predict largely due to insufficient training data, with empirical testing being heavily used to avoid challenges in late-stage antibody development. To fill this gap, we built a high-throughput antibody developability assay platform designed to generate the large datasets needed to train improved machine learning (ML) models. We optimized and automated known developability assays, and developed a robust integrated data analytics pipeline. Here, we report data on 246 antibodies - representing 106 approved, 135 clinical-stage, and 5 preregistration/withdrawn molecules - across a panel of 10 developability assays, in a "tidy data" format suitable for AI/ML modeling. We used these data to develop an XGBoost ML model that better predicts similarity to approved antibodies compared to conventional use of developability warning thresholds. Additionally, we confirm that preliminary predictive models do improve with more training data. Our high-throughput PROPHET-Ab platform enables data generation at the scale needed to develop improved ML models to predict antibody developability.
- 2 December 2025
- Published by Taylor & Francis in mAbs
- Vol. 17 (1) , 2593055
Open AccessA high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training
Antibodies must bind their targets with high affinity and specificity to achieve useful therapeutic activity. They must also possess suitable developability properties (e.g. thermostability, solubility, viscosity, polyreactivity) to ensure favorable manufacturing, formulation, and in vivo performance. Both binding and developability properties are inherent to a given antibody amino acid sequence. Identification or selection of antibodies possessing suitable-binding characteristics is now routine, and de novo computational design models, trained on extensive complementarity-determining region sequence and structural data, are rapidly improving. Developability properties, however, remain difficult to predict largely due to insufficient training data, with empirical testing being heavily used to avoid challenges in late-stage antibody development. To fill this gap, we built a high-throughput antibody developability assay platform designed to generate the large datasets needed to train improved machine learning (ML) models. We optimized and automated known developability assays, and developed a robust integrated data analytics pipeline. Here, we report data on 246 antibodies - representing 106 approved, 135 clinical-stage, and 5 preregistration/withdrawn molecules - across a panel of 10 developability assays, in a "tidy data" format suitable for AI/ML modeling. We used these data to develop an XGBoost ML model that better predicts similarity to approved antibodies compared to conventional use of developability warning thresholds. Additionally, we confirm that preliminary predictive models do improve with more training data. Our high-throughput PROPHET-Ab platform enables data generation at the scale needed to develop improved ML models to predict antibody developability.